AKT1 and mantle cell lymphoma: In support of this, treatment of all MCL cell lines with the AKT inhibitor MK-2206 or the MTOR inhibitor rapamycin resulted in growth inhibition without affecting the cell viability, similar to KIN-8194 treatment (Supplementary Fig. 4).